Skip to Main Content

Investor support for the German drug maker InflaRx (IFRX) has propelled its stock price to all-time highs this month. Other investors are shorting the stock, betting InflaRx is poised for a sharp fall.

Which side in this escalating bull-bear fight is right? The answer lies in the outcome of an ongoing clinical trial involving InflaRx’s lead drug, which aims to treat a debilitating skin disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED